|
|
Vaccine Detail
|
DIPG and GMB Immunomodulatory DC Vaccine |
| Vaccine Information |
- Vaccine Name: DIPG and GMB Immunomodulatory DC Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: immune modulatory antigens (NCT03914768)
- Immunization Route: subcutaneous injection
- Description: Immunomodulatory DC vaccines based on ex vivo genetic modifications in combination with known tumor-specific antigens may substantially enhance the activation potential of tumor-specific T cells with improved benefit to patients. This DC vaccine is based on autologous DCs pulsed with genetically modified tumor cells or related antigens such as neoantigens to induce a strong anti-tumor immunity. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg). (NCT03914768)
|
| Host Response |
|
|
| References |
NCT03914768: Immune Modulatory DC Vaccine Against Brain Tumor [https://clinicaltrials.gov/study/NCT03914768]
|
|
